Georgios Terzis - Cosmos Health Chief Officer
| COSM Stock | USD 0.81 0.02 2.53% |
Insider
Georgios Terzis is Chief Officer of Cosmos Health
| Age | 42 |
| Address | 141 West Jackson Boulevard, Chicago, IL, United States, 60604 |
| Phone | 312 536 3102 |
| Web | https://www.cosmosholdingsinc.com |
Georgios Terzis Latest Insider Activity
Tracking and analyzing the buying and selling activities of Georgios Terzis against Cosmos Health stock is an integral part of due diligence when investing in Cosmos Health. Georgios Terzis insider activity provides valuable insight into whether Cosmos Health is net buyers or sellers over its current business cycle. Note, Cosmos Health insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cosmos Health'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Georgios Terzis over a year ago Acquisition by Georgios Terzis of 51485 shares of Cosmos Health subject to Rule 16b-3 | ||
Georgios Terzis over a year ago Acquisition by Georgios Terzis of 100000 shares of Cosmos Health subject to Rule 16b-3 |
Cosmos Health Management Efficiency
The company has return on total asset (ROA) of (0.2023) % which means that it has lost $0.2023 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5661) %, meaning that it created substantial loss on money invested by shareholders. Cosmos Health's management efficiency ratios could be used to measure how well Cosmos Health manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Tangible Assets is likely to drop to -0.33. In addition to that, Return On Capital Employed is likely to grow to -0.5. At this time, Cosmos Health's Asset Turnover is very stable compared to the past year.Similar Executives
| Showing other executives | INSIDER Age | ||
| Lloyd Brathwaite | Tilray Inc | N/A | |
| Albert Bolles | Lifecore Biomedical | 66 | |
| Susumu Mitsumori | Shionogi Co Ltd | N/A | |
| Steven Esq | Catalent | 61 | |
| Michael Starkweather | Shuttle Pharmaceuticals | 40 | |
| Aaron Perlitsh | Lifecore Biomedical | N/A | |
| Julien Meissonnier | Catalent | N/A | |
| Robert Weinstein | Petros Pharmaceuticals | 64 | |
| John Minardo | Ironwood Pharmaceuticals | 48 | |
| CSC MD | Shuttle Pharmaceuticals | 57 | |
| Sravan Emany | Ironwood Pharmaceuticals | 46 | |
| J Carroll | Catalent | 70 | |
| Tyvin MD | Shuttle Pharmaceuticals | 76 | |
| CA CBV | Tilray Inc | 52 | |
| Dara Redler | Tilray Inc | N/A | |
| James Meiers | Tilray Inc | 66 | |
| Kohji Hanasaki | Shionogi Co Ltd | N/A | |
| Denise Faltischek | Tilray Inc | 51 | |
| Jason Rickard | Ironwood Pharmaceuticals | 53 | |
| Ricci Whitlow | Catalent | 51 | |
| Xiaodong Pan | China SXT Pharmaceuticals | 46 | |
Management Performance
| Return On Equity | -0.57 | ||||
| Return On Asset | -0.2 |
Cosmos Health Leadership Team
Elected by the shareholders, the Cosmos Health's board of directors comprises two types of representatives: Cosmos Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cosmos. The board's role is to monitor Cosmos Health's management team and ensure that shareholders' interests are well served. Cosmos Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cosmos Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Demetrios Demetriades, Secretary, Director | ||
| Grigorios Siokas, Chairman of the Board, CEO, CFO | ||
| Georgios Terzis, Chief Officer | ||
| Pavlos Ignatiades, Chief Officer | ||
| Nikolaos Bardakis, Chief Officer |
Cosmos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cosmos Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.57 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (0.38) % | ||||
| Operating Margin | (0.19) % | ||||
| Current Valuation | 25.19 M | ||||
| Shares Outstanding | 23.35 M | ||||
| Shares Owned By Insiders | 15.51 % | ||||
| Shares Owned By Institutions | 10.28 % | ||||
| Number Of Shares Shorted | 363.5 K | ||||
| Price To Earning | 2.41 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cosmos Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Cosmos Stock, please use our How to Invest in Cosmos Health guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cosmos Health. If investors know Cosmos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cosmos Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.45) | Revenue Per Share 3.733 | Quarterly Revenue Growth 0.068 | Return On Assets (0.20) | Return On Equity (0.57) |
The market value of Cosmos Health is measured differently than its book value, which is the value of Cosmos that is recorded on the company's balance sheet. Investors also form their own opinion of Cosmos Health's value that differs from its market value or its book value, called intrinsic value, which is Cosmos Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cosmos Health's market value can be influenced by many factors that don't directly affect Cosmos Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cosmos Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cosmos Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cosmos Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.